Executive Summary

Valued at 25.8 USD Billion in 2025, the Hospital-at-Home Technologies Market is forecast to reach 82.9 USD Billion by 2035, expanding at a CAGR of 12.36%. The 2025-2035 outlook reflects a near tripling of the base figure as remote monitoring, telehealth platforms and in-home therapeutic equipment substitute for inpatient bed-days across acute and post-acute care.

Health systems are extending reimbursement models modeled on the CMS Acute Hospital Care at Home waiver beyond the United States, pairing connected patient-monitoring devices with telehealth platforms to shift treatment out of inpatient beds. Portable diagnostic and infusion technologies are absorbing caseloads that chronic-disease programs can no longer host on hospital wards.

North America held 44.0% of the market in 2025, ahead of Europe at 29.0% and Asia Pacific at 21.0%. Patient Monitoring Devices led the product-type axis, and Acute Care at Home was the largest segment by care type as hospitals substitute wearable and bedside sensors for admission.

Reimbursement coverage outside CMS-anchored programs remains the principal constraint on scale-up, particularly for the mobile diagnostic and infusion hardware acute-level home care requires. Vendors compete chiefly on clinical evidence, monitoring-platform interoperability and payer relationships rather than on hardware price alone.

Key Takeaways

• USD 25.8 Billion in 2025, growing to USD 82.9 Billion by 2035 (12.36% CAGR).
• Patient Monitoring Devices leads product-type share, with most devices cleared through the FDA’s 510(k) or De Novo pathway; Acute Care at Home leads by care-type share.
• Telehealth & Communication Devices is the fastest-scaling product segment, extending standard-of-care monitoring into the home setting.
• North America led with 44.0% share in 2025, ahead of Europe at 29.0%, where EU MDR conformity gates market access for connected monitoring devices.
• CMS’s Acute Hospital Care at Home waiver anchors home-based acute-care reimbursement in the largest market; UK uptake follows NICE’s coverage decisions on remote monitoring.
• Reimbursement outside these anchored programs stays uneven, limiting pull-through of newly indicated devices.

Market Definition and Scope

The Hospital-at-Home Technologies Market covers the patient monitoring devices, diagnostic equipment, therapeutic equipment, and telehealth and communication devices used to deliver hospital-level acute, post-acute, chronic-disease, and rehabilitation or palliative care inside a patient’s residence in place of an inpatient admission. It spans wearable biosensors, portable imaging and point-of-care testing systems, infusion pumps, portable ventilators and oxygen concentrators, remote patient monitoring software, and video consultation platforms, deployed by hospitals, home health agencies, and payer-sponsored care-at-home programs.

The market excludes traditional home healthcare services delivered without connected monitoring or telehealth infrastructure, long-term custodial nursing-home care, and general consumer wellness wearables lacking clinical-grade monitoring or physician oversight. Hospital-based inpatient equipment that never leaves the facility, and unrelated ambulatory surgical center technologies, also sit outside this boundary.

Growth Drivers and Restraints

CMS’s Acute Hospital Care at Home Waiver Is Normalizing Reimbursement for Home-Based Acute Care

CMS launched the Acute Hospital Care at Home waiver in November 2020, permitting participating hospitals to bill Medicare for inpatient-level treatment delivered in a patient’s residence. The Consolidated Appropriations Act, 2023 extended the waiver’s authority, giving health systems a multi-year runway to build the monitoring and staffing infrastructure the model requires. That reimbursement certainty is pulling capital toward Patient Monitoring Devices and Therapeutic Equipment, the hardware needed to replicate ward-level observation and treatment at home. Acute Care at Home is the direct beneficiary: congestive heart failure, COPD exacerbation and community-acquired pneumonia, the waiver’s most common qualifying diagnoses, all depend on continuous vital-sign monitoring and infusion capability outside the hospital. North America absorbs most of this effect first, since the waiver has no direct equivalent elsewhere.

Human-in-the-Loop AI Rules Are Clearing the Path for Connected Monitoring to Scale Beyond North America

Brazil’s CFM Resolution No. 2,454/2026 establishes a human-in-the-loop regime for artificial intelligence in medical practice, permitting AI to function only as decision support while physicians retain full responsibility and patients keep a right of informed refusal. That framework gives hospital-at-home programs a compliance template for deploying AI-assisted vital-sign analysis on Wearable Biosensors and Cardiac/ECG Monitors without waiting for a bespoke national rule. The World Health Organization’s Global Strategy on Digital Health has pushed member states toward similar oversight structures for remote-monitoring software, reinforcing demand for Telehealth & Communication Devices and Remote Patient Monitoring Software that log a clear clinical audit trail. Latin America and parts of Asia Pacific stand to adopt connected monitoring fastest under this template, since it substitutes for building acute-care reimbursement rules from scratch.

EU MDR Certification Is Steering Portable Diagnostic and Therapeutic Devices Toward Home-Care Channels

Regulation (EU) 2017/745, the EU Medical Device Regulation, requires portable ultrasound, infusion pump and oxygen concentrator manufacturers selling into Europe to recertify under a stricter conformity-assessment regime than the directive it replaced. Device makers that clear MDR review are increasingly designing for home-care use cases from the outset, since a single certified platform can serve both hospital wards and Post-Acute & Transitional Care programs delivered at home. The U.S. FDA’s parallel 510(k) and De Novo pathways for connected monitoring and point-of-care testing hardware are producing the same effect domestically, giving manufacturers a cleared route to sell Portable Imaging Systems and Blood Gas & Electrolyte Analyzers directly into home-hospital programs. Europe, where hospital bed capacity is most constrained, is the primary destination for this shift.

Reimbursement Outside CMS-Anchored Programs Still Lags Acute-Level Home Care Costs

The Acute Hospital Care at Home waiver’s billing codes apply only to U.S. Medicare-participating hospitals, so health systems in markets without an equivalent national code must fund monitoring hardware, staffing and transport from operating budgets rather than per-diem reimbursement. European payers generally route coverage decisions through national health technology assessment bodies such as the UK’s NICE, a process that evaluates home-hospital programs case by case rather than under a standing reimbursement category. That gap falls hardest on Therapeutic Equipment purchases, portable ventilators, oxygen concentrators and dialysis systems, whose upfront cost is difficult to justify without a predictable payer pathway, slowing adoption outside North America even where clinical demand is present.

EU MDR Recertification Is Slowing Legacy Device Rollout Into Home-Care Settings

Portable imaging, infusion and monitoring devices already on the market under the EU’s earlier Medical Device Directive must complete new clinical-evidence dossiers to keep selling under Regulation (EU) 2017/745, and notified-body capacity to review those dossiers has not kept pace with demand. Manufacturers of legacy Portable Ultrasound Systems and Ambulatory Infusion Pumps face a choice between funding recertification for equipment nearing the end of its product cycle or withdrawing it from the European market, either of which delays the device refresh that home-hospital programs need. Smaller device makers, with thinner regulatory-affairs budgets than large multinational suppliers, are the most exposed to this bottleneck, concentrating near-term supply risk in Europe’s Post-Acute & Transitional Care segment.

Market Trends

Remote Patient Monitoring Software Is Merging With Bedside Sensor Hardware Into Single Billable Platforms

Hospital-at-home programs built around the CMS Acute Hospital Care at Home waiver bill the combined monitoring service under a single CPT/HCPCS code, so vendors are bundling Remote Patient Monitoring Software with Wearable Biosensors and Cardiac/ECG Monitors rather than seeking separate reimbursement for either device class. That bundling is happening now because coverage rules reward a documented, continuous data stream over episodic clinic readings, and acute, post-acute and chronic-disease programs increasingly depend on that continuous connected-care record to support a reimbursement claim that keeps a patient out of a hospital bed. Health systems running Acute Care at Home and Chronic Disease Management programs are the primary adopters, and the shift is pushing demand from standalone diagnostic hardware toward integrated monitoring platforms with a single market access pathway over the 2025-2035 forecast period.

Human-in-the-Loop AI Oversight Rules Are Becoming the Template for Home-Based Decision Support

Brazil’s CFM Resolution No. 2,454/2026, adopted in 2026, requires that AI used in medical practice function only as decision support, with a physician of record supervising every case and a patient’s right to refuse AI-assisted care preserved as a matter of standard of care. That rule is arriving as AI-assisted triage and alarm-prioritization software spreads through Telehealth & Communication Devices and Remote Patient Monitoring Software, where an algorithm rather than a bedside nurse now makes the first read on a vital-sign trend ahead of clinician sign-off. Post-Acute & Transitional Care and Rehabilitation & Palliative Care programs, which rely on intermittent rather than continuous clinician contact, are most affected, since they lean hardest on software to flag deterioration between visits and to document the encounter for a coverage claim. Regulators elsewhere, including agencies weighing FDA clearance pathways for clinical decision support software, are expected to follow a similar human-in-the-loop structure rather than an outright restriction on AI monitoring tools.

Portable Diagnostics Are Extending Point-of-Care Testing From the Clinic Into the Living Room

Point-of-care testing devices originally built for emergency departments, blood gas and electrolyte analyzers, coagulation analyzers and infectious-disease testing units, are being re-engineered for home use as a lower device class reaches the market under Regulation (EU) 2017/745 (EU MDR) and the FDA’s 510(k) and De Novo clearance pathways. That shift is happening now because Acute Care at Home programs need lab-quality results within the same visit rather than waiting on a courier to a hospital laboratory, and a cleared home-use label is what opens a reimbursement pathway for the test itself. Diagnostic Equipment is the segment absorbing this change most directly, with Portable Imaging Systems following as portable X-ray and ultrasound units shrink enough for a home-care bag under the same market access logic. Over the forecast period, demand shifts from centralized hospital labs toward distributed, single-patient testing capacity.

Segment Analysis

By Product Type

• Patient Monitoring Devices (largest) – Wearable or bedside sensors that track vital signs such as heart rate, blood pressure, oxygen saturation, and glucose for patients receiving acute or chronic care in the home
• Vital Sign Monitors

• Blood Pressure Monitors
• Pulse Oximeters
• Temperature Monitors

• Wearable Biosensors
• Cardiac/ECG Monitors
• Diagnostic Equipment – Portable imaging, point-of-care testing, and lab-on-a-chip devices that let clinicians or patients perform diagnostic tests such as blood work, ECGs, or ultrasound outside a hospital setting
• Point-of-Care Testing (POCT) Devices

• Blood Gas & Electrolyte Analyzers
• Coagulation Analyzers
• Infectious Disease Testing Devices
• Portable Imaging Systems

• Portable X-Ray Systems
• Portable Ultrasound Systems
• Blood Glucose Monitoring Devices
• Therapeutic Equipment – In-home devices used to deliver treatment, such as infusion pumps, oxygen concentrators, ventilators, and dialysis machines, that manage a patient’s condition without hospital admission
• Infusion Pumps

• Volumetric Infusion Pumps
• Syringe Infusion Pumps
• Ambulatory Infusion Pumps

• Portable Ventilators & Oxygen Concentrators
• Negative Pressure Wound Therapy Devices
• Portable Dialysis Systems
• Telehealth & Communication Devices – Video-conferencing platforms, remote consultation software, and connected hardware that link patients at home with clinical staff for virtual visits, triage, and care coordination

• Video Consultation Platforms
• Remote Patient Monitoring (RPM) Software
• Mobile Health Applications

Patient Monitoring Devices lead product-type demand in 2025, ranking ahead of diagnostic, therapeutic, and telehealth categories. Hospital-at-home programs anchor cost and safety on continuous vital-sign visibility. A caregiver managing a heart-failure or COPD patient outside a ward needs the same blood-pressure, oximetry, and cardiac-rhythm data a bedside monitor would supply, and payers require that data trail to authorize acute-level billing. Wearable biosensors and cardiac/ECG monitors extend that logic into ambulatory use, keeping the category ahead of diagnostic and infusion purchases.

Telehealth & Communication Devices post the fastest growth of the four categories. Video consultation platforms and remote patient monitoring software are the layer clinicians use to triage and adjust care between visits. As acute-care-at-home enrollment grows, each new patient adds a telehealth seat rather than a capital device, pulling the category ahead of hardware-heavy peers.

By Care Type

• Acute Care at Home (largest) – Hospital-level care for patients with serious illness or injury delivered in the home using mobile diagnostics, IV therapies, and remote vital-sign monitoring as a substitute for an inpatient hospital stay

• Congestive Heart Failure (CHF)
• COPD Exacerbation
• Community-Acquired Pneumonia
• Cellulitis & Skin/Soft Tissue Infections
• Urinary Tract Infections (UTI)
• Post-Acute & Transitional Care – Short-term clinical support provided after a hospital discharge or procedure, such as wound checks, medication reconciliation, and follow-up monitoring, to bridge the patient from hospital to full recovery at home

• Post-Surgical Recovery Care
• Skilled Nursing at Home
• Transitional Care Management
• Early Supported Discharge (ESD)
• Chronic Disease Management – Ongoing remote monitoring and care coordination for patients with long-term conditions like diabetes, heart failure, or COPD, using connected devices to track symptoms and adjust treatment between clinician visits

• Diabetes Management
• Heart Failure Management
• COPD Management
• Chronic Kidney Disease Management
• Hypertension Management
• Rehabilitation & Palliative Care – In-home physical therapy, functional recovery support, and comfort-focused care for patients regaining mobility after illness or surgery, or managing serious illness near end of life

• Physical & Occupational Rehabilitation
• Post-Stroke Rehabilitation
• Palliative Care
• Hospice Care

Acute Care at Home leads the care-type segmentation in 2025, the largest program category as hospitals substitute inpatient beds for congestive heart failure, COPD exacerbation, and pneumonia cases with home-based equivalents. This category carries the highest technology intensity per patient, since replacing an inpatient stay requires monitoring, diagnostic, and therapeutic devices bundled together rather than any single class. It is the configuration hospital systems build first when standing up a hospital-at-home program.

Chronic Disease Management is expanding fastest among the four care types. Diabetes, heart-failure, and COPD management increasingly rely on remote monitoring and connected-care technology to track symptoms between clinician visits. As acute-care-at-home cohorts age past their initial episode, providers are extending the same connected infrastructure into longer-term chronic management rather than discharging patients back to unmonitored care.

Regional Analysis

North America held 44.0% of the market in 2025, the largest of the three regions covered. The share traces to a specific federal mechanism. The Centers for Medicare & Medicaid Services’ Acute Hospital Care at Home waiver lets participating US hospitals bill inpatient-equivalent rates for care delivered in the home. Health systems have built monitoring and infusion capacity around that reimbursement pathway rather than around any single device category. Waiver permanence remains the variable large IDNs are building capacity against.

Europe accounted for 29.0% of the market in 2025. NHS England’s virtual ward programme is the region’s clearest anchor. It moves heart-failure, COPD, and post-surgical patients into monitored home settings as a substitute for a hospital bed, and acute trusts are held to occupancy targets that make home-based capacity a planning requirement rather than a pilot. Device makers selling into the region also face EU MDR recertification costs, which raise the bar for legacy monitoring and infusion equipment entering hospital-at-home procurement.

Asia Pacific represented 21.0% of the market in 2025, the smallest of the three regions and the base from which adoption is expanding. Japan’s Ministry of Health, Labour and Welfare has extended home-based acute care into its reimbursement schedule as the country’s hospital bed capacity is stretched by an aging population. China’s tiered hospital system is separately pushing lower-acuity recovery and chronic monitoring into community and home settings under national procurement programmes. Neither market yet matches the scale of build-out seen in the US or UK.

Competitive Landscape

The hospital-at-home technologies market is led by a group of established players spanning care-delivery operators, medical device manufacturers, and telehealth platforms. Competition centers on reimbursement contracting and health-system integration rather than device specification alone. A vendor’s value rests on whether its monitoring and communication stack can be billed under a hospital’s at-home waiver, and on how deep its clinical evidence base runs with payers. Signed agreements with a health system or IDN carry more weight than one-off device sales. Installed-base lock-in matters too: a hospital that standardizes its remote-monitoring platform across one acute-care-at-home cohort is unlikely to re-platform for the next.

Named competitors include Medically Home Group, Teladoc Health, Koninklijke Philips, GE HealthCare Technologies, Best Buy Health, Biofourmis, Cadence Solutions, Current Health, DispatchHealth, and VSee Health. The field spans large diversified device and telehealth companies alongside specialist operators built specifically around the acute-care-at-home model. That split keeps competitive intensity concentrated on clinical partnership and payer contracting rather than on price alone.

Strategic Outlook

The clearest whitespace sits in chronic disease management, where connected monitoring can extend acute-care-at-home infrastructure into long-term COPD, heart-failure, and diabetes follow-up rather than discharging patients back to unmonitored care. Realizing it depends on payers extending reimbursement parity beyond the acute episode into sustained remote monitoring.

By 2035, the technology mix is expected to shift from standalone monitoring hardware toward integrated telehealth and remote-monitoring software layered onto a smaller set of core devices, as health systems consolidate around fewer vendors capable of carrying a patient across acute, post-acute, and chronic stages within one platform.

Hospital-at-Home Technologies Market Report Scope